Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure

August 8, 2016 6:37 AM EDT
Get Alerts BMY Hot Sheet
Price: $51.96 +5.42%

Rating Summary:
    9 Buy, 13 Hold, 5 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade BMY Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Piper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) following news Friday that its CheckMate-026 (CM-026) trial of Opdivo missed its primary endpoint in the treatment of PD-L1+ expressors (>5% PD-L1+,~55-60% of patients) in first-line NSCLC (1L NSCLC). This failure was in stark contrast to Merck’s Keytruda which met the primary and secondary endpoint of Progression Free Survival (PFS) and Overall Survival (OS) in 1L NSCLC in PD-L1 high expressors (>50% PD-L1+,~25-30% of patients).

Meanwhile, the firm raised its price target on Neutral-rated Merck (NYSE: MRK) to $62.00 (from $58.00) on the same news.

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $63.28 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment